Tralokinumab for Moderate to Severe Atopic Dermatitis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Tralokinumab for Moderate-to-Severe Atopic Dermatitis: Results From Two 52-Week, Randomized, Double-Blind, Multicentre, Placebo-Controlled Phase III Trials (ECZTRA 1 and ECZTRA 2)
Br J Dermatol 2020 Sep 30;[EPub Ahead of Print], A Wollenberg, A Blauvelt, E Guttman-Yassky, M Worm, C Lynde, JP Lacour, L Spelman, N Katoh, H Saeki, Y Poulin, A Lesiak, L Kircik, SH Cho, P Herranz, MJ Cork, K Peris, LA Steffensen, B Bang, A Kuznetsova, TN Jensen, ML Østerdal, EL Simpson, ECZTRA 1 and ECZTRA 2 study investigatorsFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.